Mini-Sentinel Prospective Surveillance Program Can Assist New Drug Pharmacovigilance
This article was originally published in The Pink Sheet Daily
Known as PROMPT, the prospective monitoring system might be useful in tracking a new drug that is part of a category in which a safety issue has arisen before, or in cases where potential problems surfaced in development studies, according to researchers.
You may also be interested in...
PMDA's project for developing a medical information database infrastructure for 10 million people aims to better understand the probability for adverse effects with drugs and will enter its test period starting next year.
FDA’s Janet Woodcock used her time at a conference on biomedical innovation to highlight ways to use FDA’s Sentinel network more broadly to standardize, and hopefully streamline comparative effectiveness research.
The effort will complement the FDA-funded project’s existing ability to retrospectively measure exposure to products and then analyze specific adverse outcomes.